TTC39B in obesity and atherosclerosis
TTC39B in obesity and atherosclerosis
批准号:
10197190
负责人:
ALAN richard TALL
金额:
$54.49万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-07-15 至 2023-06-30
关键词:
ATP binding cassette transporter 1AdipocytesAdipose tissueAdrenergic AgentsAgonistAlgorithmsAntiatherogenicAntisense OligonucleotidesArterial Fatty StreakAtherosclerosisBindingBinding SitesBlood VesselsBrown FatCholesterolCo-ImmunoprecipitationsCollaborationsDiabetes MellitusE2F transcription factorsEatingEnterocytesEnzymesExcisionFamily memberFatty LiverGene ExpressionGenesGenetic TranscriptionHepaticHigh Density Lipoprotein CholesterolHigh Density LipoproteinsHumanInflammationInflammatoryInflammatory ResponseInsulin ResistanceLXRalpha proteinLinkLipolysisLipoproteinsLiverLow-Density LipoproteinsMediatingMessenger RNAMetabolicMusMyelogenousNon-Insulin-Dependent Diabetes MellitusNuclearNutritionalObesityObesity EpidemicPPAR gammaPeroxisome Proliferator-Activated ReceptorsPhospholipidsPlasmaPolyunsaturated Fatty AcidsProteinsProteomicsReceptor SignalingRegulatory ElementRepressionResolutionRetinoblastoma ProteinRoleSRE-1 binding proteinSamplingScaffolding ProteinTertiary Protein StructureTestingUbiquitinationUnited Statesadipocyte differentiationatherogenesisbeta-adrenergic receptorcalmodulin-dependent protein kinase IIgenome wide association studyinsulin sensitizing drugslipid biosynthesislipid mediatormacrophagenovel therapeuticsobesity treatmentpreservationpromoterreceptorresponsetranscription factortreatment responsewestern diet
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In human GWAS SNPs in the tetratricopeptide repeat domain protein 39B gene (TTC39B/T39)
that cause reduced hepatic expression are associated with increased HDL cholesterol. T39, a
scaffolding protein, promotes the ubiquitination and turnover of LXR. Western Type Diet (WTD)-
fed Ldlr-/-T39-/- mice showed decreased fatty liver, increased HDL, decreased LDL and reduced
atherosclerosis. T39 deficiency inhibited processing of sterol regulatory element binding protein
1 (SREBP-1) into its nuclear active form, due to an increase in microsomal phospholipids
containing polyunsaturated fatty acids (PUFA). We discovered that T39-/- macrophages also
show increased LXR., increased expression of genes mediating synthesis of PUFA, and
reduced inflammatory responses, suggesting a role of macrophages in reduced atherosclerosis
in mice with whole body T39 deficiency. Interestingly, treatment of WTD-fed Ldlr-/- mice with a
T39 antisense oligonucleotide (ASO) that decreased expression in both liver and adipose tissue
leads to reduced adiposity. While brown adipose tissue depots and food intake were
unchanged, T39 ASO treatment led to markedly increased expression of Ucp1 in WAT,
suggesting formation of beige adipocytes (beiging). We will investigate the role of T39 in
regulating LXR in macrophages and PPARγ in adipose tissue and effects on adiposity, insulin
resistance and atherosclerosis (Fig 1), linking to LXR studies in Proj 1, and of PPARγ studies in
Proj 3. Aim 1 will assess the impact of myeloid T39 deficiency on macrophage inflammation,
insulin resistance and atherosclerosis. We will explore the hypothesis that T39 deficiency
reduces ubiquitination and promotes stabilization of LXR in macrophages and thus enhances
LXR-mediated repression of inflammatory genes, primarily by increasing the synthesis of
phospholipids containing long chain PUFA. With Dr Tabas, we will determine if macrophage T39
deficiency promotes inflammation resolution.To determine if myeloid T39 deficiency is anti-
atherogenic, we will breed LysM-CreT39f/f mice in the Ldlr-/- background. Aim 2 will assess the
impact of adipocyte T39 deficiency on adiposity, insulin resistance and atherosclerosis. We will
breed AdipoQ-CreT39f/f mice in order to deplete T39 in WAT and assess adiposity, beiging and,
on the Ldlr-/- background, plasma lipoproteins and atherosclerosis. With Drs Accili and Qiang,
we will examine the impact of T39 deficiency on formation of beige adipocytes from the stromal-
vascular fraction (SVF). We will assess a specific hypothesis that T39 deficiency decreases the
binding of Rb family members to the E2F binding site in the promoter of Pparg1and other
beiging genes, promoting formation of beige adipocytes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New therapeutic approaches in clonal hematopoiesis and atherosclerosis
-
批准号:10719058
-
项目类别:
-
资助金额:$69.47万
-
财政年份:2023
-
负责人:ALAN richard TALL
-
依托单位:
Clonal hematopoiesis, inflammasomes and atherosclerosis
-
批准号:10581564
-
项目类别:
-
资助金额:$54.41万
-
财政年份:2021
-
负责人:ALAN richard TALL
-
依托单位:
Clonal hematopoiesis, inflammasomes and atherosclerosis
-
批准号:10339390
-
项目类别:
-
资助金额:$54.41万
-
财政年份:2021
-
负责人:ALAN richard TALL
-
依托单位:
TTC39B in Metabolism
-
批准号:10064114
-
项目类别:
-
资助金额:$47.35万
-
财政年份:2014
-
负责人:ALAN richard TALL
-
依托单位:
TTC39B in Metabolism
-
批准号:10308034
-
项目类别:
-
资助金额:$46.69万
-
财政年份:2014
-
负责人:ALAN richard TALL
-
依托单位:
TTC39B in Metabolism
-
批准号:9386771
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2014
-
负责人:ALAN richard TALL
-
依托单位:
TTC39B in Metabolism
-
批准号:8962161
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2014
-
负责人:ALAN richard TALL
-
依托单位:
Hyperinsulinemia, mTOR activity and plasma lipoproteins
-
批准号:8275590
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2012
-
负责人:ALAN richard TALL
-
依托单位:
ABCA1/G1 and LXRs in Atherogenesis
-
批准号:10171606
-
项目类别:
-
资助金额:$51.04万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
ABCG1 and endothelial function
-
批准号:8207861
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
ABCA1/ABCG1 in myeloid populations and atherogenesis
-
批准号:8675919
-
项目类别:
-
资助金额:$39.45万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
ABCA1/G1 and LXRs in Atherogenesis
-
批准号:10406915
-
项目类别:
-
资助金额:$50.26万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
ABCA1/ABCG1 in myeloid populations and atherogenesis
-
批准号:8085576
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
ABCG1 and endothelial function
-
批准号:8038742
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
ABCA1/G1 and LXRs in Atherogenesis
-
批准号:8889088
-
项目类别:
-
资助金额:$40.38万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
ABCA1/ABCG1 in myeloid populations and atherogenesis
-
批准号:8269807
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
ABCA1/ABCG1 in myeloid populations and atherogenesis
-
批准号:8465264
-
项目类别:
-
资助金额:$38.32万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
ABCG1 and endothelial function
-
批准号:8402623
-
项目类别:
-
资助金额:$38.32万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
ABCA1/G1 and LXRs in Atherogenesis
-
批准号:9889981
-
项目类别:
-
资助金额:$51.79万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
Cholesterol efflux, CHIP and inflammasome activation
-
批准号:10735980
-
项目类别:
-
资助金额:$61.69万
-
财政年份:2011
-
负责人:ALAN richard TALL
-
依托单位:
国内基金
海外基金
支链氨基酸代谢紊乱调控“Adipocytes - Macrophages Crosstalk”诱发2型糖尿病脂肪组织功能和结构障碍的作用及机制
-
批准号:81970721
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:陶凌
-
依托单位: